When data during and immediately after tariquidar administration were excluded, an average fivefold reduction in Q out was observed in rats.
Patients less than 20 years of age, with body mass index (BMI) more than 35, and with psychiatric diseases, mental retardation, history of asthma, and contraindication for suxamethonium administration, were excluded from the study.
Women who were pregnant (based on serum human chorionic gonadotropin levels) or lactating, had used oral or transdermal hormonal contraceptives within 21 days of drug administration, or had used implanted, injected, intravaginal, or intrauterine hormonal contraceptives within 6 months of drug administration were excluded.
Subjects who experienced the pandemic 2009 A/H1N1 influenza infection or vaccine administration were excluded by carefully reviewing the influenza related clinical records or history.
Data for hospitalisation due to planned chemotherapy administration were excluded.
Patients on haemodialysis pre-contrast or who died within 48 hours post-contrast administration were excluded.
But pregnant women who were referred from other health institutions outside Bahir Dar city administration were excluded from the study.
Mice that were not hyperglycemic (fed BG > 400 mg/dl) 3 days after STZ administration were excluded from further study.
Studies primarily involving patients with exacerbations of chronic pulmonary disease, acute lung injury and perioperative administration were excluded.
Because bevacizumab, another MAb indicated for CRC, is also associated with IRs, patients with claims of bevacizumab administration within 14 days of cetuximab administration were excluded.
Therefore, central venous catheter insertion and pulse oximetry were retained, while central venous infusion and oxygen administration were excluded from the analysis.
